Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $27.7M | $251M | $272M | $225M | $253M | $228M | $236M | $230M | $228M |
| Revenue growth | — | — | 806.6% | 8.5% | -17.3% | 12.5% | -9.9% | 3.3% | -2.2% | -0.9% |
| Operating income | -$277M | -$292M | -$94.7M | -$39.0M | -$30.4M | $1.29M | $23.7M | $32.6M | $31.0M | $37.3M |
| Operating margin | — | -1056.1% | -37.7% | -14.3% | -13.5% | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Net income | -$276M | -$292M | -$114M | -$75.6M | -$60.0M | -$29.1M | $2.00K | $21.6M | $30.3M | $31.1M |
| Net margin | — | -1054.6% | -45.3% | -27.8% | -26.7% | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (diluted) | -$8.29 | -$7.85 | -$2.99 | -$1.95 | -$1.52 | -$0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$142M | -$172M | -$24.1M | $22.4M | $773K | $20.6M | -$15.8M | $27.0M | $38.9M | $41.8M |
| Capital expenditures | $4.29M | $431K | $439K | $306K | $46.0K | $0.00 | $0.00 | $140K | $56.0K | $71.0K |
| Free cash flow | -$146M | -$173M | -$24.5M | $22.1M | $727K | $20.6M | -$15.8M | $26.9M | $38.9M | $41.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $194M | $81.7M | $108M | $60.0M | $85.3M | $63.1M | $76.2M | $84.6M | $69.2M | $29.6M |
| Total assets | $253M | $166M | $259M | $235M | $244M | $227M | $222M | $231M | $213M | $216M |
| Total liabilities | $43.0M | $112M | $225M | $217M | $250M | $229M | $200M | $177M | $121M | $86.0M |
| Long-term debt | — | $48.5M | $152M | $95.0M | $84.0M | $97.1M | $98.3M | $65.7M | $21.7M | $0.00 |
| Shareholders' equity | $210M | $53.3M | $34.3M | $17.5M | -$5.95M | -$2.45M | $21.6M | $53.4M | $92.1M | $130M |
| Retained earnings | -$797M | -$1.09B | -$1.20B | -$1.28B | -$1.34B | -$1.37B | -$1.37B | -$1.35B | -$1.31B | -$1.28B |
| Shares (wtd avg diluted) | 36.8M | 37.6M | 38.3M | 39.2M | 39.6M | 40.6M | 44.9M | 47.6M | 49.1M | 50.7M |
Every figure is extracted from PUMA BIOTECHNOLOGY, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.